



FORM PTO-1449 INFORMATION DISCLOSURE STATEMENT	DOCKET NO.: 701039-	SERIAL NO.: 09/469,637
	54682-C1-CPA	
	APPLICANT(S): Marsha A. Moses, et al.	
	FILING DATE: 12/22/99	GROUP NO.: 1651

UNITED STATES PATENT DOCUMENTS

EXAM. INITIALS	DOCUMENT NUMBER	DATE	INVENTOR/ASSIGNEE	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE

RECEIVED
DEC 24 2003
TECH CENTER 1600/2900

FOREIGN PATENT DOCUMENTS


DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION YES/NO

OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.)

<i>RC</i>	CG	Howard, E. et al, "Presence of Matrix Metalloproteinases in Urine from Bladder Cancer Patients," Proceeding of American Association for Cancer Research Annual Meeting, Vol 35, pp. 17 (1994).
<i>RC</i>	CH	Davies, et al., "Levels of matrix Metalloproteinases in Bladder Cancer Correlate with Tumor Grade and Invasion," Cancer Research 53, pp. 5365-5369 (1993).

RETURNED 3/22/04

APPLICANT FACSIMILE OF FORM PTO-1449 REV 7-80	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY DOCKET NO CME-083CPCN	SERIAL NO. 09/469,637
LIST OF PUBLICATIONS CITED BY APPLICANT (Use several sheets if necessary)		APPLICANT Marsha A. Moses et al.	
		FILING DATE December 22, 1999	GROUP 1651



U.S. PATENT DOCUMENTS

EXAMINER	CLASSIFICATION	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
RG	AA	5,270,447	12/93	Liotta et al.	530	326	
	AB	5,324,634	06/94	Zucker	435	7.23	
	AC	5,344,760	09/94	Harvey et al.	435	7.5	
	AD	5,482,848	01/96	Dickson et al.	435	219	

FOREIGN PATENT DOCUMENTS


	CLASSIFICATION	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
							YES	NO
RG	AE	685 557	06/95	EPO				
	AF	691 409	10/96	EPO				
	AG	WO 90/10228	09/90	PCT				
	AH	EP 0 430 642	06/91	EPO				
	AI	WO 91/11714	08/91	PCT				
	AJ	JP 03 290 199	12/91	Japan			abst	
	AK	WO 92/01936	02/92	PCT				
	AL	WO 94/25434	11/94	PCT				
	AM	WO 93/20447	10/93	PCT				

OTHERS (including Author, Title, Date, Pertinent Pages, Etc.)

RG	AN	Attallah, A. et al., "Comparative Study Between Cytology and Dot-ELISA for Early Detection of Bladder Cancer", <i>A.J.C.P.</i> , Vol. 102, No. 1, pp. 109-114 (1996);
	AO	Basta, M. et al., "Cytokeratin Shedding in Urine: A Biological Marker for Bladder Cancer?", <i>British Journal of Urology</i> , Vol. 61, pp. 116-121 (1988);
	AP	Blaser, J. et al., "A Sandwich Enzyme Immunoassay for the Determination of Neutrophil Lipocalin in Body Fluids", <i>Clinica Chimica Acta</i> , Vol. 235, pp. 137-145 (1995);
	AQ	Bogdanowicz, J. et al., "Evaluation of Prostate-Specific Antigen and Prostatic Acid Phosphatase in Untreated Prostatic Carcinoma and Benign Prostatic Hyperplasia", <i>Scand. J. Urology Nephrol. Suppl.</i> , Vol. 138, pp. 97-103 (1991);
	AR	Braunhut, S. et al., "Retinoids Modulate Endothelial Cell Production of Matrix-degrading Proteases and Tissue Inhibitors of Metalloproteinases (TIMP)", <i>Journal of Biological Chemistry</i> , Vol. 259 (18):13472-13479 (1994);
	AS	Breul, J. et al., "Prostate-Specific Antigen in Urine", <i>Eur. Urol.</i> , Vol. 26, pp 18-21 (1994);

Examiner RG BITOMEN	Date Considered 3/22/04
*EXAMINER Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

APPLICANT FACSIMILE OF FORM PTO-1449 REV 7-80	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY DOCKET NO CME-083CP	SERIAL NO. 08/843,095
PUBLICATIONS CITED BY APPLICANT (See several sheets if necessary)		APPLICANTS Marsha A. Moses et al.	
		FILING DATE April 25, 1997	GROUP 1651



OTHERS (including Author, Title, Date, Pertinent Pages, Etc.)

RG	BA	Carr, M. et al., "Urinary Levels of the Renal Tubular Enzyme N-Acetyl-β-D-Glucosaminidase in Unilateral Obstructive Uropathy", <i>The Journal of Urology</i> , Vol. 151, pp. 442-445 (1994);
	BB	Fernandez-Luna, J. et al., "Measurement of Protein HC (α ₁ microglobulin) and protein HC-IgA complex in different body fluids", <i>J. Clin. Pathol.</i> , Vol. 41, pp. 1176-1179 (1988);
	BC	Fine, R., et al., "Accumulation of Urinary Cancer-related Glycoprotein, EDCl, in Psoriasis", <i>Journal of Investigative Dermatology</i> , Vol. 73, pp. 264-265 (1979);
	BD	Garnick, M., "Prostate Cancer: Screening, Diagnosis, and Management", <i>Annals of Internal Medicine</i> , Vol. 118, pp. 804-818 (1993);
	BE	Garnick, M., "The Dilemmas of Prostate Cancer", <i>Scientific American</i> , Vol. 270 (4), pp. 72-81 (1994);
	BF	Grover, P. et al., "Analysis of Prostatic Fluid: Evidence for the Presence of a Prospective Marker for Prostatic Cancer", <i>The Prostate</i> , Vol. 26, pp. 12-18 (1995);
	BG	Ho, K. et al., "Urinary Beta-Glucuronidase Activity as an Initial Screening Test for Urinary tract Malignancy in High Risk Patients", <i>Cancer</i> , Vol. 76, No. 3, pp. 473-478 (1995);
	BH	Jones, A. et al., "Urinary N-acetyl-β-glucosaminidase Activity in Type I Diabetes Mellitus", <i>Ann Clin Biochem</i> , Vol. 32, pp. 58-62 (1995);
	BI	Kossakowska, A. et al., "Tissue Inhibitor of Metalloproteinases-1 (TIMP-1) RNA Is Expressed at Elevated Levels in Malignant Non-Hodgkin's Lymphomas", <i>Blood</i> , Vol. 77 (11), pp. 2475-2481 (1991);
	BJ	Lee, M. et al., "Analysis of Affinity and Structural Selectivity in the Binding of Proteins to Glycosaminoglycans: Development of a Sensitive Electrophoretic Approach", <i>Biochemistry</i> , Vol. 88, pp. 2768-2772 (1991);
	BK	Liotta, L. et al., "Cancer Metastasis and Angiogenesis: An Imbalance of Positive and Negative Regulation", <i>Cell</i> , Vol. 64, pp. 327-336 (1991);
	BL	Lu, X. ET AL., "Immunological Quantitation of Levels of Tissue Inhibitor of Metalloproteinase-1 in Human Colon Cancer", <i>Cancer Research</i> , Vol. 51, pp. 6231-6235 (1991);
	BM	Margulies, I. et al. "Urinary Type IV Collagenase: Elevated Levels Are Associated with Bladder Transitional Cell Carcinoma" <i>Cancer Epidemiology, Biomarkers & Prevention</i> , Vol. 1, pp. 467-474 (1992);
	BN	Miller, D. et al., "Purification and Characterization of Active Human Interleukin 1β-converting Enzyme from THP.1 Monocytic Cells", <i>Journal of Biological Chemistry</i> , Vol. 268 (24), pp. 18062-18069 (1993);
✓	BO	Moses, M. et al., "Production of Matrix Metalloproteinases and a Metalloproteinase Inhibitor by Swarm Rat Chondrosarcoma", <i>Biochemical and Biophysical Research Communications</i> , Vol. 199 (1), pp. 418-424 (1994);

Examiner RGI Tomsen	Date Considered 3/22/04
------------------------	----------------------------

*EXAMINER Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

APPLICANT FACSIMILE OF FORM PTO-1449 REV 7-90 U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE

ATTY DOCKET NO: **CMZ-083CPCNCPA** SERIAL NO.: **09/469651**

APPLICANT: **Moses, Marsha A. et al.**

FILING DATE: **February 20, 2002** GROUP: **1623/651**

OIPE
LIST OF PUBLICATIONS CITED BY APPLICANT
(Use several sheets if necessary)

JUN 16 2003

PATENT & TRADEMARK OFFICE

RECEIVED
TECH CENTER 1600/3900
JUN 18 2003

U.S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
RG	A0 6,210,912 B1	04/01	Koyama et al.	435	7.4	

FOREIGN PATENT DOCUMENTS

DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION YES NO

OTHERS (including Author, Title, Date, Pertinent Pages, Etc.)

RG	A1	Bianco, F.J. et al. "Matrix metalloproteinase-9 expression in bladder cancer patients predicts pathological stage and grade." <i>Clinical Cancer Research</i> 4(10):3011-6 (Dec. 1998).
RG	A2	Durkan, G.C. et al. "Prognostic significance of matrix metalloproteinase -1 and tissue inhibitor of metalloproteinase-1 in voided urine samples from patients with transitional cell carcinoma of the bladder." <i>Clinical Cancer Research</i> 7(11):3450-6 (Nov. 2001).
	A3	Kanno, N. et al. "Effects of epidermal growth factor on the invasion activity of the bladder cancer cell line." <i>Journal of Urology</i> 159(2):586-90 (Feb. 1998).
	A4	Koshida, K. et al. "Prospects for molecular research in urological oncology: bladder cancer." <i>Acta Urologica Japonica</i> 47(11):815-8 (Nov. 2001) [Japanese with English abstract].
	A5	Levitt, N.C. et al. "Phase I and pharmacological study of the oral matrix metalloproteinase inhibitor, MMI270 (CGS27023A), in patients with advanced solid cancer." <i>Clinical Cancer Research</i> 7(7):1912-22 (Jul. 2001).
	A6	Mizushima, Y. et al. "Diuretic response to cyclophosphamide in rats bearing a matrix metalloproteinase -9-producing tumour." <i>British Journal of Cancer</i> 78(8):1030-4 (Feb. 1998).
	A7	Özdemir, E. et al. "Role of matrix metalloproteinase-9 in the basement membrane destruction of superficial urothelial carcinomas." <i>Journal of Urology</i> 161(4):1359-63 (Apr. 99).
	A8	Pattari, S.K. et al. "Urine: beyond cytology for detection of malignancy." <i>Diagnostic Cytopathology</i> 27(3):139-42 (Sep. 2002).
✓	A9	Yan, L. et al. "The high molecular weight urinary matrix metalloproteinase (MMP) activity is a complex of gelatinase B/MMP-9 and neutrophil gelatinase-associated lipocalin (NGAL). Modulation of MMP-9 activity by NGAL." <i>Journal of Biological Chemistry</i> 276(40):37258-65 (5 Oct. 2001).

Examiner: RGltomer Date Considered: 7/3/03

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.